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ABSTRACT
The incidence of uterine fibroids, which comprise one of the most common female pelvic tumors, is almost 70–75% for 
women of reproductive age. With the development of surgical techniques and skills, more individuals prefer minimally 
invasive methods to treat uterine fibroids. There is no doubt that minimally invasive surgery has broad use for uterine 
fibroids. Since laparoscopic myomectomy was first performed in 1979, more methods have been used for uterine fibroids, 
such as laparoscopic hysterectomy, laparoscopic radiofrequency volumetric thermal ablation, and uterine artery emboliza-
tion, and each has many variations. In this review, we compared these methods of minimally invasive surgery for uterine 
fibroids, analyzed their benefits and drawbacks, and discussed their future development. 
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INTRODUCTION
Uterine fibroids comprise one of the most common 
female pelvic tumors. When including the small, clinically 
undetectable fibroids and microscopic fibroids, the incidence 
is approximately 70–75% for those of reproductive age. The 
cause of uterine fibroids is not clear, and most fibroids pre-
sent with no symptoms. Only 20–50% fibroids have obvious 
symptoms, submucous type particularly, for example, abnor-
mal uterine bleeding, urinary frequency or retention, obvious 
abdominal or pelvic pressure, and infertility. Most fibroids do 
not need treatment. However, indications for therapy include 
anemia resulting from metrorrhagia, pelvic pain or pressure 
affecting daily life, uterine compression, rapid tumor growth, 
tumor growth after menopause, and infertility [1].
The first laparoscopic myomectomy was performed by 
Semm in 1979 [2], and it may be the first minimally invasive 
surgery recorded. Since then, there have been numerous 
advancements in minimally invasive surgery for uterine 
fibroids. With the increasing of number of surgical methods 
and development of surgical techniques, uterine fibroid 
surgery is becoming easier, more feasible, and less inva-
sive and results in fewer complications. Minimally inva-
sive surgery has been considered an advanced approach 
for dealing with uterine fibroids. In 2014, Chittawar et al 
performed a meta-analysis to compare minimally invasive 
surgical techniques and open myomectomy for uterine 
fibroids. They found that those two kinds of surgery did 
not have different recurrence risks, but that laparoscopic 
myomectomy may be associated with less postoperative 
pain, lower postoperative fever, and shorter hospital stays 
compared with all other types of open myomectomy [3]. 
Minimally invasive surgery truly has its own advantages 
when dealing with uterine fibroids.
In this review, we compared the techniques, methods, 
and complications of many types of minimally invasive 
surgery to analyze their indications, advantages, and dis-
advantages (Tab. 1). We also evaluated their development 
status and have provided some evidence of the future de-
velopment of minimally invasive surgery for uterine fibroids.
Laparoscopic hysterectomy
In 1989, Harry Reich performed the first laparoscopic 
hysterectomy [4]. Laparoscopic hysterectomy has devel-
oped into many types, with three of most common being 
total laparoscopic hysterectomy (TLH), laparoscopic-assisted 
vaginal hysterectomy (LAVH), and laparoscopic supracervi-
cal hysterectomy (LASH).
Total laparoscopic hysterectomy (TLH)
The TLH procedure has some features of laparoscopic 
surgery and abdominal hysterectomy. The use of the trocar 
is comparable to that of conventional laparoscopic myomec-
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tomy. Pneumoperitoneum with 10–14 mmHg needs to be 
created and three trocars are usually needed. The advantages 
of TLH compared with traditional abdominal hysterectomy 
include faster recovery, less intraoperative blood loss, less 
postoperative pain, and enhanced cosmetic appearance. 
Surgeons have discussed the largest fibroid weight that is 
still treatable with TLH. In 2017, Antonio et al reported TLH for 
a uterus containing 5352 g of fibroids [5]. Therefore, uterine 
size may no longer be a factor that influences whether to use 
laparoscopic hysterectomy. However, according to a multi-
variable analysis, there are some factors that present a high 
risk for conversion to open surgery, such as the surgeon’s ex-
perience and fibroids with a maximum diameter > 10 cm [6]. 
Laparoscopic-assisted vaginal hysterectomy (LAVH)
Most LAVH procedures are akin to TLH, except for the 
vaginal procedure. The vaginal procedure begins after co-
agulating and resecting the ovarian ducts and proper ovar-
ian ligaments. Surgeons should first dissect the bladder from 
the surface of the uterine and then open the Douglas pouch. 
Then, surgeons resect and ligate the cardinal ligament and 
enter the vesicouterine pouch. The next step is to ligate 
and resect the uterine arteries so that the uterus can be 
removed. Finally, hemostasis and suturing of the vaginal 
walls are performed before proceeding with the normal 
laparoscopic hysterectomy [7]. The greatest merits of LAVH 
compared with conventional abdominal hysterectomy are 
its reduced morbidity and faster recovery. The main factor 
limiting the use of LAVH is the uterine size. Although the 
maximum uterine size for LAVH is based on the experience 
and proficiency of the surgeon, when the uterine weight is 
more than 800 g, LAVH may not be appropriate because of 
the significant blood loss or other complications. However, 
LAVH may be safe for patients with a uterine size ≤ 12 cm [7].
Laparoscopic supracervical hysterectomy (LSH)
The LSH procedure is contrary to that of TLH except 
for the preservation of the cervical stump and vaginal and 
uterosacral ligaments; therefore, the operative procedure is 
obviously simplified and the possibility of accidental injury 
to the surrounding organs such as the bladder, intestine, 
and ureter is reduced. Its indications are wider than those 
for LAVH; they include pain and/or uterine enlargement 
caused by myomata, dysfunctional uterine bleeding with 
no response to treatment, suspected uterine adenomyo-
sis, and bleeding after endometrial ablation or resection. 
LASH is also suitable for nulliparous patients who have not 
experienced a vaginal delivery. It is a new minimally inva-
sive alternative with low preoperative morbidity for total 
hysterectomy with benign conditions. Furthermore, LASH 
has benefits such as shorter hospital stays, faster recovery, 
and faster return to the workplace [8]. 
Research has been performed to determine the differ-
ences between TLH, LAVH, and LSH. LSH may involve lower 
serum AMH levels, more ovarian function reserve, low rates 
of re-operation and spotting, and better quality of life and 
sexual function than TLH [ 9–11]. Previous gynecologic con-
ditions were also associated with the type of laparoscopic 
hysterectomy (LH) performed. Patients with a previous ce-
sarean delivery and previous hysteroscopy are more likely 
to undergo LSH than LAVH. However, TLH is more suitable 
than LSH for patients who have undergone previous pelvic 
surgery. Estimated blood loss, operative time, and length 
of hospital stay were significantly reduced with LSH. Fur-
thermore, LSH was the most common approach and was 
associated with significantly less morbidity [12]. 
Laparoscopic myomectomy
Laparoscopic myomectomy was first described by Semm 
in 1979; at that time, it was only used for subserous fibroids. In 
the early 1990s, this procedure was also used for intramural 
fibroids [13]. Currently, laparoscopic myomectomy is a com-
mon procedure for infertile patients. It is indicated for many 
conditions such as the presence of subserous or intramu-
ral fibroids that narrow the uterine cavity, myomas (which 
can be larger than 3 cm), or multiple fibroids. Compared with 
traditional open myomectomy, laparoscopic myomectomy 
may have less of an effect on ovarian function, the serum pain 
index, and the oxidative damage index, and it may result in 
higher successful pregnancy rate. However, the recurrence 
rate with laparoscopic myomectomy might also be higher 
[14, 15]. The general opinion is that the fibroid must have 
gradually emerged and have a maximal size of 8–10 cm, and 
the total number of uterine fibroids should not exceed four 
or five [16]. Laparoscopic myomectomy is also associated 
with complications such as uterine rupture during pregnancy 
or labor, embolism, thrombosis, bowel injury, ureter injury, 
urinary bladder injury, excessive bleeding, and fistula.
With the constant development of techniques and in-
struments, the range of application for laparoscopic my-
omectomy is becoming wider, the procedure is becoming 
more intricate, and the complications are decreasing. Lapa-
roscopic myomectomy has gradually improved; it results 
in reduced pain, shorter recovery time, and less ileus time 
than conventional laparotomy.
There are four different laparoscopic myomectomy ap-
proaches: laparoscopic-assisted abdominal myomectomy 
(LAAM); laparoscopic-assisted vaginal myomectomy (LAVM); 
total laparoscopic myomectomy (TLM); and isobaric lapa-
roscopic myomectomy.
Laparoscopic-assisted abdominal myomectomy (LAAM)
LAAM was first performed by Nezhat et al. [17] in 
1994. There is some concern that laparoscopy cannot be used 
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to approach the exact wound site and realize the same he-
mostasis as conventional laparotomy; therefore, hematoma 
might occur after surgery. With LAAM, the fibroids are iso-
lated, followed by a Mini-laparotomy. Therefore, laparoscopic 
suturing can be avoided. Compared with conventional lapa-
roscopic myomectomy, LAAM is superior because it provides 
exact multilayer suturing, requires less complex technology, 
reduces the operative time, and results in similar recovery 
time. Furthermore, during laparoscopy, the general use of 
electrocoagulation hemostasis may injure the uterine tissues.
Laparoscopic-assisted vaginal myomectomy
During LAVM, a guide suture is usually placed to identify 
the largest tumor after laparoscopic identification of the 
location of all fibroids. Then, a culdotomy incision was made, 
through which the guide suture can be taken out of the 
uterus and placed in the vagina by using a grasper. These 
procedures usually involve enucleation and removal of the 
fibroids or repair of the uterine injury and hemostasis [1].
The benefits of LAVM are comparable to those of LAAM. 
However, there are some differences in the location of the fi-
broids. Generally, LAAM is used to manage fibroids develop-
ing in the anterior uterine or pedunculated fibroids, whereas 
LAVM is more suitable for posterior fibroids. The difficulty 
of LAVM is determined by the vaginal capacity. Therefore, 
LAVM is not recommended for nulliparous women and those 
with a contracted pelvis.
Total laparoscopic myomectomy
TLM is still considered a difficult laparoscopic procedure 
because repairing the uterine defect can be challenging. 
TLM has limited indications, such as fundal or subserosal 
myomas. Laparoscopic enucleation of large or deep intra-
mural fibroids remains debatable. To solve this problem, 
Yuen et al. [18] proposed an improved laparoscopic suturing 
technique that involves the surgeon manually controlling 
the tail of the suture while sewing laparoscopically. However, 
this method may be of little value for the skilled surgeons.
Isobaric laparoscopic myomectomy
Most laparoscopic myomectomy procedures use CO2 to 
build pneumoperitoneum; however, when the myoma is 
large (≥ 8 cm), surgery may be hampered because of the 
increased operative time, risk of preoperative bleeding, and 
risk of conversion to laparotomy [19]. Hence, a new method 
called isobaric laparoscopic myomectomy was developed. 
With this method, surgeons use a laprotenser to lift the ab-
dominal wall so that a vertical intraumbilical incision can be 
made. Then, primary access is realized by inserting a 10-mm 
to 11-mm trocar through that incision, and two lower inci-
sions are made without trocars lateral to the rectus mus-
cles. The incision on the right side is 15 mm to 20 mm, and 
that on the left side is 10 mm [19]. Therefore, under direct 
visualization, conventional long laparoscopic instruments 
can be used. An irrigation-suction cannula and bipolar cau-
tery are pivotal for the procedure. Isobaric laparoscopic 
myomectomy has a few advantages. First, it avoids building 
pneumoperitoneum, thereby avoiding the side effects and 
potential risks of CO2. Second, because the peritoneal cavity 
does not need to maintain pressure-tight, conventional, 
long laparotomy instruments, including knives, scissors, and 
tissue clamps, needle holders can be used. This facilitates 
several steps of the procedure, including uterine repair. 
Third, operative costs and operative times are reduced. 
Furthermore, this method is more easily learned by surgeons 
who are experienced with laparotomy.  
Trocar placement
Correcting the trocar placement is a crucial factor that 
influences the surgical procedure. Traditionally, surgeons 
place three portals during surgery. However, with develop-
ments in the surgery technique and the higher demand for 
the operation, more portal sites are being used, and each 
has its own merits.
Conventional portal sites and the Lee-Huang point
The conventional use of three portal sites is good for 
medium masses. Video-assisted laparoscopy was performed 
through the umbilicus using a 5-mm or 10-mm principal 
trocar. Two ancillary cannulas are placed with the help of 
video-assisted laparoscopy: one 5-mm trocar in the right 
lower quadrant beside the inferior epigastric arteries and the 
other 5-mm trocar in the left lower quadrant [1]. However, 
with the demand for larger fibroids, Lee et al. introduced 
new portal sites called the Lee-Huang point. The principal 
cannula is placed at the midpoint between the umbilicus 
and the diploid process. Another two 5-mm puncture sites 
are made at the intersection of the bilateral paramed-
ian line and the level of umbilicus. If three portal sites are 
not enough, then other trocars can be selected just above 
the pubic hairline and at the level of the paramedian line.
This type of placement has many advantages. First, the 
placement of the first trocar (the Lee-Huang point) is much 
safer for patients with a history of pelvic surgery, potential 
malignancies, and large pelvic masses. This placement of the 
cannulas avoids the major bloods vessels and nerves. Sec-
ond, the incision through the linea alba accesses the abdomi-
nal cavity better, provides a better visual field, and increases 
the accuracy when resecting large myomas. Therefore, using 
the Lee-Huang point may be the best choice for large masses.
Laparoendoscopic single-site myomectomy 
Some research has demonstrated that laparoendoscopic 
single-site myomectomy (LESS-M) is suitable for patients 
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with fewer than five myomas and offers outcomes akin 
to those of conventional laparoscopic myomectomy after 
surgeons master the technique [20]. However, LESS has 
not been widely popularized because of its difficult tech-
nique that involves limited motion or clashing between 
instruments. Another challenge for LESS-M is that after the 
large tissue specimens are removed through the umbilical 
incision, the uterine walls need multiple sutures; therefore, 
repair of the uterine wall injuries may be difficult for sur-
geons with limited experience. Furthermore, difficulties in 
maintaining adequate tension of the suture line and trying 
to accurately create a knot increase the operative time and 
intraoperative blood loss. Only a wound retractor and a sur-
gical glove can fit in a single port entry. A vertical incision of 
15–20 mm was made through the umbilicus; then, two 
5-mm cannulas and one 12-mm cannula were inserted with 
the first, third, and fifth fingers of the surgical glove and fixed 
with silk ligatures. Next, the glove was fixed at the outer ring 
of the wound retractors. After repair of the myometrium, 
surgeons use an electromechanical morcellator, which is 
usually 15 mm, to enucleate myomas, and that device can be 
placed with one free gloved finger [20].
Although difficult, LESS-M has some advantage. Obvi-
ously, its cosmetic benefits are greater than those of other 
surgery types. Some studies showed that LESS can reduce 
postoperative pain more than conventional laparoscopic 
surgery [21]. For instance, the lower abdomen large trocar 
insertions of conventional laparoscopic surgery may in-
crease the risk of trocar-related sequela, such as incisional 
hernias [22].
Choi’s four-trocar method
In 2006, Choi et al. [23] introduced the four-trocar meth-
od, which provides a better operation field for the large 
uterus. The method uses four trocars for patients whose 
uterus is same size as it at approximately 16 to 18 weeks of 
pregnancy. With the guidance of a central 5-mm telescope, 
the placement of the first trocar is usually the supraumbili-
cal region. Another two 5-mm ancillary trocars are placed 
lateral to the superior and inferior epigastric vessels in the 
left and right upper quadrants. The level of the upward shift 
can be modulated by the uterine size. The fourth trocar is 
placed 2 cm above the symphysis pubis so that the four 
5-mm trocar points can form a V-shape.
This technique has many benefits. First, surgeons can ob-
tain a larger surgical field to exclude the myoma. Second, all 
the trocars are situated in the “safe zone” to avoid potential 
injury to the surrounding nerves and vessels, especially the 
ilioinguinal or iliohypogastric nerves and the inferior epigas-
tric arteries. Third, the risk of intestinal herniation and the scar 
size are reduced because only 5-mm trocar ports and one 
12-mm cannula are used for the myoma screw or morcellator.
However, some believe that because the uterus is large, 
the placement of the primary trocar in the umbilical region 
makes the working distance shorter and the operation field 
smaller. It may be difficult for surgeons to view the whole 
pelvis, large uterus, and tumors. Therefore, the Lee-Huang 
point, may be a better option.
Two-port total laparoscopic myomectomy
Two-port total laparoscopic myomectomy (TTLM) was 
performed using only umbilicus and left inguinal ports. An 
Olympus 5-mm flexible scope was used to visualize the 
surgical field, regardless of the insertion angle, and a 12-
mm trocar was placed at the umbilical incision. However, 
for the patients with a history of open abdominal surgery, 
the ninth intercostal approach is necessary to confirm the 
absence of any adhesion of the abdominal organs and the 
umbilicus [24].
The technique has the same technical difficulty as the 
conventional technique, and it allows exact suturing of 
the myometrium (2 to 4 layers) assuming the myomas be-
ing removed are within the indicated limits. Furthermore, 
the two-port technique provides a much higher degree of 
freedom when handling forceps and adjusting the surgical 
field of view than single-port myomectomy.
Is morcellation an Achilles heel?
Electrical morcellators have been used during lapa-
roscopy; however, they are associated with complications, 
including major vascular, bowel, ureteric, kidney, and dia-
phragmatic injuries [25]. These complications are rare. Other 
less immediately obvious and long-term complications as-
sociated with electrical morcellators are more common. 
A morcellator is in fact a cylinder device with a cutting tip 
that can rotate rapidly. It cuts the tumor into strips and then 
collects those strips in its hollow cylindrical body. However, 
some of the strips will fall out of the device and must be 
collected and removed individually. However, some small 
particles or cells in microscopic quantities can spin off and 
cannot be removed. These may develop into disseminated 
peritoneal leiomyomatosis in the future. Characteristics of 
this type of disease include multiple smooth muscle nod-
ules that can develop sub-peritoneally and can be found 
in any part of the abdominal cavity; although morbidity is 
rare and most cases remain benign, some may progress to 
cancer [26]. It may be not worth the risk and lead to a poor 
prognosis for patients.
An animal model that was established to study the 
mechanism of the parasite myoma found that estrogen 
has an important role. Implanted myomas possess more 
estrogen receptor (ER) and more progesterone receptors 
(PR), and they have more angiogenesis and proliferative 
properties compared with non-implanted myomas. Estro-
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gen depletion will significantly decrease laparoscopically 
induced parasite myoma implantation. The implantation, 
angiogenesis, and proliferation of parasite myomas may 
be associated with serum E2 levels. Sex steroid hormone 
modulators and aromatase inhibitors (AI) may also decrease 
implantation, angiogenesis, and proliferation. These data 
revealed that angiogenesis and implantation induced by 
estrogen have an important role in the development of 
parasite myomas, and that hormonal modulation with AI 
could potentially prevent laparoscopically induced parasite 
myomas [27].
In clinical practice, surgeons have created many meas-
ures to prevent parasite myomas. A thorough pelvic lav-
age is required during surgery because it may reduce the 
cellular load. Some surgeons use a plastic bag to collect 
morcellation materials and then dilate the navel scar to 
3–4 cm so the bag can be removed through the navel [28]. 
Some experts think that avoiding the use of an electronic 
morcellator can achieve satisfactory tumor reduction dur-
ing laparoscopic surgery. Reich et al. introduced a method 
using conventional surgical tools, such as a scalpel, that 
can morcellate the largest tumors. This method only re-
quires a small incision in the abdominal wall to insert the 
device [29]. Another specifically designed morcellator knife 
has been shown to decrease the loss of the tissue during 
surgery [30]. Many types of new morcellation tools are in 
varying degrees of development. For example, devices that 
can be used outside the abdomen, such as with the vaginal 
approach, are being developed.
Laparoscopic radiofrequency volumetric thermal 
ablation (RFVTA)
Laparoscopic radiofrequency volumetric thermal abla-
tion (RFVTA) based on primary liver ablation was developed 
by Lee in 2002 [31]. The equipment used for RFVTA treatment 
include a monopolar radiofrequency generator, a handpiece 
with an electrode tip, two electrode pads, extension cables, 
an activating foot pedal, and other equipment. Current is 
delivered to the small electrode tip to ablate the fibroid 
tissue, which is removed via two large dispersive electrode 
pads that are usually placed on the patient’s thighs. When 
the electrical current decreases, it results in the oscillation 
of intracellular ions, thus generating resistive or frictional 
heating. During the procedure, the heat decreases rapidly 
with the increasing distance from the electrode. The current 
continues to flow from the handpiece to the electrode pads; 
at the same time, the myomas undergo ablation and be-
come coagulative and necrosis. Finally, they are reabsorbed 
by the surrounding tissues.
As a minimally invasive and uterine-sparing procedure, 
RFVTA has many advantages that cannot be duplicated. 
More fibroids can be detected using laparoscopic ultra-
sound intraoperatively than with either transvaginal ultra-
sound or contrast-enhanced magnetic resonance imaging 
(MRI) [32]; therefore, it is suitable for more cases such as 
large fibroids, multiple fibroids, and deep intramural fi-
broids [33], but not for type 0 (pedunculated) intracavitary 
fibroids, which are best suited to undergo hysteroscopic 
resection. Because RFVTA uses flowing current to coagu-
late fibroids, there is less blood loss and no laparoscopic 
uterine suturing, which is difficult for many surgeons. Sur-
geons only need to use intracutaneous sutures to close the 
port sites; therefore, patients often have minimal injury 
and leave the hospital on the same day as the surgery 
[34]. Furthermore, RFVTA provides significant reductions 
in uterine size, significant reductions in or elimination of 
myoma symptoms, and significant improvements in qual-
ity of life [35]. The reproductive outcomes of RFVTA are also 
positive. Berman et al. analyzed the pregnancy outcomes 
of six women who conceived 3.5 to 15 months after the 
treatment of one to seven myomas that were between 
1.0 and 7.6 cm at the greatest diameter and were of mul-
tiple types. Five of the women delivered full-term, healthy 
newborns and one had a spontaneous abortion during the 
first trimester. Because RFVTA is a new minimally invasive 
alternative for uterine myoma, further investigations are 
needed to determine whether it is appropriate treatment 
for women who desire future fertility.
Some research has focused on comparing the differ-
ences between RFVTA and laparoscopic myomectomy, 
which is a classic minimally invasive option. It was found 
that RFVTA results in shorter hospitalizations, less blood 
loss, and a greater percentage of fibroids treated/excised 
than laparoscopic myomectomy [36]. Although laparoscopic 
myomectomy may cause a more significant improvement 
in health-related quality of life and decreased symptom 
severity scores, laparoscopic myomectomy and RFVTA may 
have equivalent safety and patient-reported efficacy [37].
Laparoscopic myolysis
The Nd YAG laser was first considered an alternative to 
laparoscopic myomectomy in 1989 because for some cases, 
such as those involving multiple intramural myomas, laparo-
scopic myomectomy is too difficult or too time-consuming. 
Indications for laparoscopic myolysis include pelvic pain 
caused by myoma, compression symptoms, or global uter-
ine volumes equivalent to those between 9 and 12 weeks of 
pregnancy [38]. The Nd YAG laser technique involves bring-
ing the tissue fiber into the center of the myoma so that the 
fibroids can be coagulated. The diameter of fibroids suitable 
for myolysis usually range from 3 to 8 cm. The mean de-
crease in the myoma diameter after myolysis was 41% after 
6 months. However, laparoscopic myolysis also has some 
complications, such as severe pain caused by coagulation of 
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the myomas, the risk of uterine rupture during pregnancy, 
uterine abscesses, and pelvic adhesions [39].
Uterine artery embolization
Uterine artery embolization (UAE) was first created in 
1995 to treat typical uterine fibroids [40]. It may be an alter-
native to traditional treatment, especially for women with 
multiple fibroids, very large fibroids, restricted operability, or 
a history of multiple operative procedures in the abdomen 
[41]. UAE has some contraindications, including viable preg-
nancy, active infection, and suspected uterine, cervical, or ad-
nexal malignancy [42]. However, UAE has many advantages, 
such as less blood loss, shorter operative times, and shorter 
hospital stays [43]. The technique also has some limitations 
that prevent its widespread application, such as postembo-
lization syndrome, which includes complete amenorrhea 
[44], subclinical damage of the ovarian function (especially 
in women older than 45 years) [45], and the potential risk of 
reintervention or subsequent hysterectomy [46]. Further-
more, the time required for the procedure and the radiation 
exposure also prevent the application of UAE [47]. UAE is 
not suitable for women who want to preserve their fertility.
Regarding the prognosis for UAE, Davis et al discussed 
the reintervention rates among myomectomy, UAE, and 
endometrial ablation (EA). They found that 5 years after 
surgery, the reintervention rate for UAE was lower than that 
for EA but higher than that for myomectomy. Prior anemia, 
bleeding, pelvic inflammatory disease, and pelvic pain might 
increase the risk of reintervention [48]. Karlsen et al reported 
that UAE may lead to lower pregnancy rates and higher mis-
carriage rates than myomectomy [49]. Therefore, although 
UAE is a safe method with many benefits, patient selection 
and counseling are important.
Laparoscopic uterine artery ligation (LUAL)
The principle of laparoscopic uterine artery ligation 
(LUAL) is similar to that of UAE. Both the right and left uterine 
arteries need to be ligated by the hemoclips, followed by 
bipolar coagulation. LUAL can overcome the complications 
of UAE. However, more research and comparisons, such as 
with hysterectomy and LAVH, are needed.
Magnetic resonance-guided ultrasound
Magnetic resonance (MR)-guided ultrasound is not 
widely used because of the costly equipment required. Fur-
thermore, few long-term randomized studies have been 
performed. MR-guided ultrasound is composed of two 
parts. MRI is used for treatment planning and synchronous 
treatment monitoring. Ultrasound is used for necrotizing 
tissue, which involves heating the fibroids to 60 to 80°C 
and leads to a reduction in fibroid size. Absolute contrain-
dications for the technique are ongoing pregnancy and 
all contraindications for MRI. However, large fibroid size 
itself is not a contraindication. Furthermore, some com-
plications may occur, such as skin burns, postoperative 
pain, nausea, and allergic reactions [50]. Therefore, more 
clinical research is necessary to verify the value and safety 
of this technique.
CONCLUSIONS
Because uterine fibroids are one of the most common 
female pelvic tumors, the development of operative meth-
ods of their treatment will continue. Furthermore, because 
of the rapid progression of operative techniques and sur-
gical skills, more surgeons and patients prefer minimally 
invasive methods to treat uterine fibroids. At first, minimally 
invasive surgery could only be used to treat small subse-
rous fibroids. Now, the indications for minimally invasive 
surgery are becoming broader, case reports are increasing, 
fibroid sizes are becoming larger, the number of fibroids 
is increasing, and fibroid locations are becoming more re-
mote. However, are these surgeries obligatory? Minimally 
invasive surgery has more shortcomings than traditional 
laparotomy, such as the longer operative times, the lower 
suturing accuracy, and the greater potential for pelvic adhe-
sions. More research is necessary to evaluate the indications 
for minimally invasive surgery to determine whether the 
outcomes are worth the risks.
Currently, electrical morcellation is a crucial compo-
nent of minimally invasive surgery because it can help 
decrease invasiveness and hasten the surgery. However, 
electrical morcellation has some side effects, such as parasite 
myomas. Parasite myomas can develop in any part of the 
abdominal cavity, and multiple smooth muscle nodules 
can develop sub-peritoneally. Although its morbidity is rare 
and most cases are benign, some may progress to cancer. 
Many solutions have been suggested for this complication, 
but none has been promoted worldwide. 
The main purpose of minimally invasive surgery is to 
decrease injury during surgery and shorten the recovery 
time. Achieving this goal cannot be accomplished with only 
minimally invasive surgery. According to enhanced recovery 
after surgery (ERAS), many measures are necessary, from 
preparation before surgery to recovery after surgery, such 
as bowel preparation and adaptive training before surgery, 
fluid management and temperature control during surgery, 
and analgesia and retention of the drainage tube after sur-
gery, among others. Minimally invasive surgery should be 
a component of ERAS so that minimal invasiveness and 
faster recovery can be realized.
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